{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:42:29Z","timestamp":1789134149546,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.016","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T13:20:12Z","timestamp":1710163212000},"page":"2463-2474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1671-0682","authenticated-orcid":false,"given":"Kota","family":"Senpuku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Kataoka-Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Kunishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-1664","authenticated-orcid":false,"given":"Toshiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-9221","authenticated-orcid":false,"given":"Yasuo","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.016_b0005","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","article-title":"The life cycle of non-polio enteroviruses and how to target it","volume":"16","author":"Baggen","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0010","article-title":"Enterovirus D68 molecular and cellular biology and pathogenesis","volume":"296","author":"Elrick","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2024.03.016_b0015","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1080\/21505594.2021.1960106","article-title":"The pathogenesis and virulence of enterovirus-D68 infection","volume":"12","author":"Sooksawasdi Na Ayudhya","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2024.03.016_b0020","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/S1473-3099(15)00543-5","article-title":"Global emergence of enterovirus D68: a systematic review","volume":"16","author":"Holm-Hansen","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.016_b0025","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.3389\/fmicb.2018.02677","article-title":"Enterovirus D68 - the new polio?","volume":"9","author":"Cassidy","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0030","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2666-5247(21)00312-8","article-title":"Enterovirus D68: a test case for the use of immunological surveillance to develop tools to mitigate the pandemic potential of emerging pathogens","volume":"3","author":"Nguyen-Tran","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2024.03.016_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/v10020058","article-title":"A mouse model of enterovirus D68 infection for assessment of the efficacy of inactivated vaccine","volume":"10","author":"Zhang","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.03.016_b0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.antiviral.2018.11.013","article-title":"A neonatal mouse model of enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis","volume":"161","author":"Sun","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2024.03.016_b0045","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00705-020-04676-6","article-title":"Single B cells reveal the antibody responses of rhesus macaques immunized with an inactivated enterovirus D68 vaccine","volume":"165","author":"Zheng","year":"2020","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198528","article-title":"Development of an experimental inactivated vaccine from vero cell adapted enterovirus D68","volume":"304","author":"Raychoudhuri","year":"2021","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2024.03.016_b0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.016_b0060","doi-asserted-by":"crossref","unstructured":"Elveborg S, Monteil VM, Mirazimi A. Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes. Pathogens 2022; 11.","DOI":"10.3390\/pathogens11020271"},{"key":"10.1016\/j.vaccine.2024.03.016_b0065","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.03.016_b0070","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jviromet.2014.07.003","article-title":"Hydrogen peroxide inactivation of influenza virus preserves antigenic structure and immunogenicity","volume":"207","author":"Dembinski","year":"2014","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2024.03.016_b0080","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.vaccine.2015.12.041","article-title":"Inactivation of rabies virus by hydrogen peroxide","volume":"34","author":"Abd-Elghaffar","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.016_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0027-5107(00)00019-1","article-title":"Hydroperoxide-induced DNA damage and mutations","volume":"450","author":"Termini","year":"2000","journal-title":"Mutat Res"},{"key":"10.1016\/j.vaccine.2024.03.016_b0090","doi-asserted-by":"crossref","unstructured":"Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, et al. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front Immunol 2017; 8: 943.","DOI":"10.3389\/fimmu.2017.00943"},{"key":"10.1016\/j.vaccine.2024.03.016_b0095","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2024.03.016_b0100","first-page":"17","article-title":"A two-dose hepatitis B vaccine for adults (Heplisav-B)","volume":"60","author":"Anonymous","year":"2018","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.vaccine.2024.03.016_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59((R)) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.016_b0110","doi-asserted-by":"crossref","first-page":"1224634","DOI":"10.3389\/fimmu.2023.1224634","article-title":"A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice","volume":"14","author":"Tokunoh","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0115","doi-asserted-by":"crossref","first-page":"e20005","DOI":"10.1371\/journal.pone.0020005","article-title":"Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.016_b0120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121882","article-title":"Enterovirus D68 infection induces IL-17-dependent neutrophilic airway inflammation and hyperresponsiveness","volume":"3","author":"Rajput","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2024.03.016_b0125","doi-asserted-by":"crossref","first-page":"e1000138","DOI":"10.1371\/journal.ppat.1000138","article-title":"Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling","volume":"4","author":"Geeraedts","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2024.03.016_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000759","article-title":"Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes","volume":"2","author":"Koyama","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.03.016_b0135","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.coviro.2011.07.002","article-title":"Innate and adaptive immune responses to viral infection and vaccination","volume":"1","author":"Aoshi","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00705-017-3592-x","article-title":"Suppression of the toll-like receptor 7-dependent type I interferon production pathway by autophagy resulting from enterovirus 71 and coxsackievirus A16 infections facilitates their replication","volume":"163","author":"Song","year":"2018","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0145","article-title":"TLR7 is critical for anti-viral humoral immunity to EV71 infection in the spinal cord","volume":"11","author":"Lin","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0150","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/JVI.73.3.1941-1948.1999","article-title":"Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification","volume":"73","author":"Oberste","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1126\/science.1261962","article-title":"Structure and inhibition of EV-D68, a virus that causes respiratory illness in children","volume":"347","author":"Liu","year":"2015","journal-title":"Science"},{"issue":"vez007","key":"10.1016\/j.vaccine.2024.03.016_b0160","article-title":"Intra- and interpatient evolution of enterovirus D68 analyzed by whole-genome deep sequencing","volume":"5","author":"Dyrdak","year":"2019","journal-title":"Virus Evol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0165","doi-asserted-by":"crossref","first-page":"e1010515","DOI":"10.1371\/journal.ppat.1010515","article-title":"Evolution, geographic spreading, and demographic distribution of Enterovirus D68","volume":"18","author":"Hodcroft","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2024.03.016_b0170","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nbt.1766","article-title":"A mucosal gateway for vaccines","volume":"29","author":"McGhee","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2024.03.016_b0185","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJM199309093291115","article-title":"Vaccine-associated paralytic poliomyelitis","volume":"329","author":"Mermel","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.03.016_b0190","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1586\/erv.09.152","article-title":"Development of enterovirus 71 vaccines","volume":"9","author":"Lee","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.016_b0195","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/jpids\/piy124","article-title":"Current understanding of humoral immunity to enterovirus D68","volume":"7","author":"Vogt","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2024.03.016_b0200","doi-asserted-by":"crossref","unstructured":"Gilrane VL, Zhuge J, Huang W, Nolan SM, Dhand A, Yin C, et al. Biennial Upsurge and Molecular Epidemiology of Enterovirus D68 Infection in New York, USA, 2014 to 2018. J Clin Microbiol 2020; 58.","DOI":"10.1128\/JCM.00284-20"},{"issue":"eadg6076","key":"10.1016\/j.vaccine.2024.03.016_b0205","article-title":"EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination","volume":"9","author":"Krug","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2024.03.016_b0210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.03.016_b0215","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/21645515.2018.1426420","article-title":"Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo","volume":"14","author":"Yao","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.03.016_b0220","doi-asserted-by":"crossref","first-page":"2149352","DOI":"10.1080\/22221751.2022.2149352","article-title":"Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism","volume":"12","author":"Du","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.016_b0225","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0230","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/JVI.75.11.5141-5150.2001","article-title":"Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection","volume":"75","author":"Tumpey","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0235","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1086\/521304","article-title":"Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine","volume":"196","author":"Ichinohe","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.016_b0240","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1016\/j.vaccine.2009.04.074","article-title":"PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants","volume":"27","author":"Ichinohe","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.016_b0245","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/intimm\/dxu063","article-title":"Challenges in mucosal vaccines for the control of infectious diseases","volume":"26","author":"Azegami","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0250","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.03.016_b0255","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/vim.2017.0022","article-title":"Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a promising influenza vaccine candidate","volume":"30","author":"Ainai","year":"2017","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0260","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1038\/s41598-018-28281-5","article-title":"A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.016_b0265","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1007\/s00705-019-04418-3","article-title":"Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice","volume":"164","author":"Chen","year":"2019","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0270","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41392-022-01002-1","article-title":"Intranasal administration of a recombinant RBD vaccine induces long-term immunity against omicron-included SARS-CoV-2 variants","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2024.03.016_b0275","doi-asserted-by":"crossref","first-page":"e0118021","DOI":"10.1128\/JVI.01180-21","article-title":"The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses","volume":"95","author":"Kawai","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0280","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.chom.2016.09.013","article-title":"ICAM-5\/Telencephalin is a functional entry receptor for enterovirus D68","volume":"20","author":"Wei","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2024.03.016_b0285","doi-asserted-by":"crossref","unstructured":"Sun J, Hu XY, Yu XF. Current understanding of human enterovirus D68. Viruses 2019; 11.","DOI":"10.3390\/v11060490"},{"key":"10.1016\/j.vaccine.2024.03.016_b0290","first-page":"11","article-title":"Understanding enterovirus D68-induced neurologic disease: a basic science review","author":"Hixon","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2024.03.016_b0295","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1099\/vir.0.79925-0","article-title":"Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses","volume":"85","author":"Oberste","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2024.03.016_b0300","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41426-017-0005-x","article-title":"Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice","volume":"7","author":"Zhang","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2024.03.016_b0305","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.vaccine.2017.12.057","article-title":"A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice","volume":"36","author":"Dai","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:31:29Z","timestamp":1723059089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003037"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}